Pharma BD Deal Intelligence
A USD 1B pathway-defence payment in the franchise both partners already own
Full analysis, sources & comparables →Sanofi and Regeneron expanded their long-standing global antibody alliance on October 1, 2026 to add four next-generation, long-acting immunology antibodies targeting IL-13, an IL-4xIL-13 bispecific, IL-4 and IL-4 receptor alpha. Sanofi pays US$1 billion upfront with up to US$7 billion in development, regulatory and commercial milestones, for total potential consideration of up to US$8 billion. The most advanced asset, REGN20423, is a clinical-stage IL-13 monoclonal antibody in Phase 1 for atopic dermatitis; the remaining three antibodies are expected to enter clinical studies in 2027. Regeneron leads discovery and development while Sanofi leads global commercial execution, with development costs and global profits shared equally. The companies also settled prior litigation in connection with the expanded collaboration.
A USD 1B pathway-defence payment in the franchise both partners already own
Assessment window: 5yr post-close.
Note: this deal's 5-year assessment window closes ~2031; the outcome grade above is a projected assessment, not yet finalized.
Atopic dermatitis (eczema) is the most common chronic inflammatory skin disease. NIAID puts U.S. prevalence at 10-30% of children and 2-10% of adults. It is the anchor indication of the type 2 inflammation market that Dupixent (dupilumab, anti-IL-4R alpha) built, and remains the commercial proving ground for next-generation IL-4/IL-13 pathway biologics.
REGN20423, the most advanced of the four in-licensed antibodies, is a clinical-stage anti-IL-13 monoclonal antibody in Phase 1 for atopic dermatitis. Long-acting dosing is the competitive lever: it targets the dosing-frequency weakness of incumbent biologics in the same pathway the partners already dominate.
Type 2 inflammation is the shared immunological axis across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and related conditions, driven largely by IL-4 and IL-13 signalling through IL-4 receptor alpha. The Sanofi-Regeneron alliance already commercialises the category-defining asset in this pathway, and the four antibodies added in this expansion are all directed at the same axis.
Three of the four antibodies (IL-4 x IL-13 bispecific, anti-IL-4, anti-IL-4 receptor alpha) are expected to enter clinical studies in 2027, so the deal is a pathway-defence play across the whole type 2 franchise rather than a single-indication bet.
Sanofi and Regeneron expanded their global antibody alliance to cover four next-generation long-acting immunology antibodies targeting IL-13, an IL-4 x IL-13 bispecific, IL-4 and IL-4 receptor alpha. Sanofi pays USD 1 billion upfront with up to USD 7 billion in development, regulatory and commercial milestones. Regeneron leads discovery and development; Sanofi leads global commercial execution, with development costs and global profits shared equally.
The companies settled prior litigation in connection with the expanded collaboration, removing a live dispute between the two parties to the Dupixent alliance.
The IL-4 x IL-13 bispecific, the anti-IL-4 antibody and the anti-IL-4 receptor alpha antibody are expected to enter clinical studies in 2027; REGN20423 is already in Phase 1 for atopic dermatitis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi S.A. / Regeneron Pharmaceuticals, Inc. (this deal) | 2026 | $8.0B | 64 |
| Sanofi S.A. / Boehringer Ingelheim GmbH (consumer healthcare business swap) | 2016 | $25.1B | 84 |
| Sanofi S.A. / Vicebio Ltd. | 2025 | $1.6B | — |
| Sanofi S.A. / Seawolf Therapeutics | 2026 | $1.2B | — |
| Arcturus Therapeutics, Inc. / CSL Seqirus (CSL Limited) | 2026 | $28M | 100 |
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
← Browse all deals · How we score deals
More: 2026 deals · Sanofi S.A. deals